For over 15 years, Dr Anthony Shum, a pulmonologist at the University of California, San Francisco has been studying a rare genetic disorder called the COPA Syndrome. It stands for coatomer subunit alpha and is a rare, inherited disorder that affects the lungs, joint, and kidney. The National Organization for Rare Disorder also notes that it is a genetic autoimmune disorder that is caused by mutations in the COPA gene. This disease affects families unpredictably—some individuals with the mutation develop severe lung damage early in life, while others remain completely healthy. Now, Shum’s team has discovered a protective genetic variant that may offer new hope for treatment.

A Breakthrough

Researchers found that some relatives of COPA Syndrome patients stayed healthy despite carrying the same COPA gene mutation that causes the disease. The key difference? These unaffected individuals had a protective version of another gene called HAQ-STING.

When scientists introduced HAQ-STING into diseased lung cells from COPA patients, the cells returned to a balanced state, suggesting that this gene could be used as a therapy.

“We really think HAQ-STING could be a gene therapy tool and a step toward a cure,” said Shum, whose findings were published in the Journal of Experimental Medicine.

Families Who Solved The Mystery

Shum’s journey into COPA Syndrome research began in 2011 when he treated a young woman, Letasha, who had severe lung bleeding. Her mother, Betty Towe, mentioned that Letasha’s sister, Kristina, had suffered from similar symptoms. Over the years, Betty had taken both daughters on a four-hour trip to UCSF for treatment. After tracing their family history, Shum discovered that their distant relatives in Texas and Oakland also had lung problems and arthritis. In 2015, Shum, along with scientists from Baylor College of Medicine and Texas Children’s Hospital identified the COPA gene mutation. They realized that it was the common factor behind the illness. However, only some of the 30 individuals with the mutation actually developed symptoms, leaving a major question unanswered.

The Domino Effect

It was established that it occurs when a mutated COPA gene causes another gene STING to go overdrive. The STING that helps fight infections in COPA patients, remain permanently active, which leads to chronic inflammation that damages the lungs, kidneys, and joints. In 2020, while studying STING’s role in the disease, researchers discovered a key variation: HAQ-STING. This version of STING, present in about one-third of the population, appeared to neutralize the harmful effects of the COPA mutation.

To confirm their theory, the scientists needed both affected and unaffected family members to participate in the testing. Letasha, Kristina and Betty immediately volunteered. The researchers then analyzed DNA samples from 26 COPA patients and their healthy relatives. They also conducted CT scans and blood tests to ensure that unaffected members did not have any hidden symptoms. When the findings were all clear, it was revealed that all the healthy individuals had HAQ-STING, while none of the COPA patients did. This was the first known case of a common gene variant completely protecting against a severe genetic disease.

Encouraged by this discovery, researchers tested HAQ-STING’s effects in a lab setting. They introduced it into diseased lung cells from COPA patients, and the cells returned to normal function.

Way Ahead

Shum believes HAQ-STING could lead to game-changing treatments, including:

• Prenatal gene therapy for babies diagnosed with COPA Syndrome before birth
• Aerosol delivery of HAQ-STING for adults, directly targeting the lungs

Before publishing their findings, Shum called Betty with the news—her own HAQ-STING gene had protected her from the disease. He also informed Letasha and Kristina, who were overwhelmed with relief and joy.

“We always believed Dr. Shum would get to the bottom of it,” said Letasha. “This discovery is going to change lives.”

Beyond lung cancers, air pollution fine particulate matter (PM2.5) is increasing mortality for breast as well as liver cancers, according to a global study led by the Union for International Cancer Control (UICC), including researchers from the Indian Council of Medical Research (ICMR).

The important study showed that long-term exposure to PM2.5 increases the overall risk of developing cancer and the chances of dying from it compared with those living in cleaner environments.

For every 10 micrograms per cubic meter (µg/m³) increase in PM2.5 exposure, the overall risk of cancers increases by more than 11 per cent. At the same time, the risk of death also increases by more than 12 per cent for every 10 µg/m³ increase in PM2.5 exposure.

The researchers argued that while other common risk factors like tobacco and alcohol are being targeted with notable progress, air pollution is silently eroding the gains being made.

“We have made huge strides in reducing deaths from cancer, but polluted air is silently undermining that progress. It is a risk people cannot opt out of, and one that disproportionately affects women, children, and people living in poverty,” Cary Adams, CEO, UICC.

“The cancer community continues to make progress in addressing other major risk factors, including tobacco use, alcohol consumption, and viral, bacterial, or parasitic infections such as HPV and HBV that cause cervical and liver cancers. It is increasingly clear that air pollution must also be recognized as a major and preventable factor that increases the risk of developing cancer and of dying from the disease,” added Dr Elisabete Weiderpass, Director, IARC.

Risks of PM2.5: Beyond Lung Cancer

The study, based on data from 42 meta-analyses and systematic reviews published between 2019 and 2024, showed significantly strong associations for liver, colorectal, and breast cancers.

As per recent data from the International Agency for Research on Cancer (IARC), PM₂.₅ exposure contributes to 434,000 lung cancers per year, accounting for more than a quarter of preventable lung cancers in women and nearly one in six in men.

In addition to lung cancer risk, the study noted that the rising levels of PM2.5 are associated with

• a 32 per cent higher incidence of liver cancer
• an 18 per cent increase in the odds of developing colorectal cancer.

• a 12 per cent higher overall risk of dying from cancer,
• a 20 per cent higher risk of death from breast cancer,
• a 14 per cent from liver cancer,
• a 12 per cent from lung cancer.

Who Is At A Higher Risk

According to the researchers, people living in low- and middle-income countries bear the greatest overall burden. These countries frequently lack the resources to reduce pollution at source or to provide timely access to cancer prevention, diagnosis, and treatment.

The challenge is compounded by the projected rise in global cancer cases, expected to increase from 20 million in 2022 to 35 million by 2050. People at risk include:

• Women and children, particularly in settings where solid fuels are used for cooking and heating.
• Women exposed to household air pollution face a 69 per cent higher risk of lung cancer, alongside increased risks of cervical cancer.
• Outdoor workers and communities living near industrial facilities are also at heightened risk, with exposure often concentrated in economically deprived areas.

What Actions Are Required?

The researchers underscored that the evidence presented in the report is already sufficient to justify decisive action to reduce exposure to polluted air. They called upon policymakers to make required changes across energy, transport, industry, and urban planning to reduce the risk of cancer from air pollution.

The study urged the need for properly implementing effective interventions that are well-established. These include:

• Stronger emissions standards and enforcing the WHO air quality Standards
• A transition to clean energy and clean cooking
• Improved urban design by investing more in green infrastructure
• Expanded air-quality monitoring in High-Risk Areas
• Update cancer control plans.

During the summer, it is important to stay hydrated, but for kidney patients, excessive intake of fluids is just as dangerous as not drinking enough. Most people are encouraged to drink extra fluids during hot weather; however, patients with chronic kidney disease (CKD) and those on dialysis must exercise greater control over their daily hydration and fluid intake because their bodies cannot effectively excrete excess fluids, leading to potential complications.

What is overhydration?

Dr Anupam Roy, Additional Director – Nephrology and Kidney Transplant at Aakash Healthcare Multi-Specialty Hospital, Dwarka, said, “Overhydration occurs when the body retains more fluid than it is able to eliminate. For kidney patients, overhydration typically leads to fluid overload as a result of excessive fluid accumulation in the body. Early signs of fluid overload may include swelling in the feet, ankles, and/or face. If not treated, fluid may continue to build up and cause the lungs to fill with fluid, resulting in shortness of breath and difficulty lying down. If left untreated, gaseous exchange in the lungs will be impaired, and the patient will require immediate medical treatment for pulmonary oedema (a life-threatening complication).”

What happens when you are overhydrated?

The effect of excess fluid on the heart and blood pressure is considered a significant concern. Excess fluid results in additional strain on the cardiovascular system, leading to high blood pressure. This extra workload may also increase the risk of serious complications (e.g., heart failure) for individuals who already have hypertension or heart disease. Dialysis patients are at particular risk of developing complications since they rely on regularly scheduled treatments to remove excess fluid. Excessive fluid consumption between dialysis sessions may complicate and increase the discomfort associated with removing excess fluid during dialysis.

How does overhydration affect kidney disease patients?

Overhydration may also cause an imbalance in electrolytes, such as sodium. Consuming a large amount of water without adequate intake of electrolytes could dilute sodium in the bloodstream, resulting in hyponatraemia. Symptoms of hyponatremia vary from mild (nausea and headaches) to severe (confusion, seizures, and, in extreme cases, coma). This condition can potentially be life-threatening for kidney disease patients, who often have difficulty maintaining an optimal balance of electrolytes.

Many people forget that they can obtain fluids from certain foods and drinks, such as soup, yogurt, watermelon, and tea or juice. In the summertime, people tend to consume these types of foods and drinks more often, which can cause them to exceed the recommended daily fluid intake. Many also believe that drinking extra water will flush toxins out of their system; however, when the kidneys are not functioning properly, excess fluids can be difficult to remove from the body.

How much water should kidney patients drink?

Dr Roy said that proper hydration for someone with kidney disease needs to be planned carefully. The amount of fluid a person can consume depends on their stage of kidney disease, urine output, and whether they are on dialysis. Some simple strategies can help maintain proper hydration: use small cups for drinks, consume fluids throughout the day rather than all at once, avoid foods high in salt (as these increase thirst), and track daily fluid intake.

The main reason for drinking fluids is to ensure the right amount is consumed; therefore, the most important aspect of hydration is maintaining balance. Maintaining this balance can help prevent complications and allow individuals to remain as healthy as possible. When kidney patients understand their hydration needs and receive proper guidance during the summer, they can avoid causing further harm by placing additional strain on their bodies.

The U-WIN (Universal Immunization Win) platform has been transformative and has helped India tackle the concerning burden of zero-dose children, said Dr NK Arora, an immunization expert and member of the National Technical Advisory Group on Immunisation in India (NTAGI).

In an exclusive conversation with HealthandMe during World Immunization Week 2026, Dr Arora, Executive Director of The INCLEN Trust International, traced the journey of the U-WIN portal and explained how it has strengthened vaccine uptake in the country.

U-WIN is a digital platform and app to help people find vaccination centers near their residences, manage vaccination appointments at health facilities, and maintain vaccination records.

Dr Arora noted that the U-WIN portal created a digital ecosystem that played a critical role in registration, appointment scheduling, vaccine tracking, and real-time monitoring.

The Origin Of U-WIN

U-Win was launched in October 2024 and is available in 12 languages, including English.

Dr Arora, also the chair of the COVID-19 and HPV vaccine working group, shared that during the deadly COVID pandemic in 2020—around July—it became very clear that to vaccinate 140 crore people, some kind of IT platform is needed that will track individuals who had been vaccinated, especially when they needed their second dose, and later, booster doses.

“Everything started somewhere around July 2020, and by January 2021, we had the Co-WIN platform. By mid-April, things were streamlined. The platform gives us a long list of individuals who have been vaccinated. It also helps to know who has been left out of the vaccination.

“It is like a registry of human beings who are getting immunized. And we could send reminders, we could send certificates, and we can also tell the individual when to get their second and third dose,” the expert said.

He noted that as COVID became less intense toward the end of 2021, serious discussions began on using the same platform for routine immunization. This is where the concept of U-WIN came in 2022. It has now been piloted and is gradually being used.

U-WIN: Closing the Gap For Missed and Zero-Dose Children

The UWIN now has the mechanism to ensure that immunization is completed for everyone who registers. One user can register up to 10 people in one mobile number, including citizens/guardians, pregnant women, infants (0-1 years), children (1-7 years), and adolescents (7-19 years).

“The key issue is that tracking provides two or three important inputs. First, it ensures that everyone is getting vaccinated and that it is not dependent on memory. There is a proper record—whether a person or child has received vaccines and what their current status is, including whether the schedule is complete,” Dr Arora said.

“Second, one of the main reasons for missing or delaying the next dose was that mothers often did not remember. Fathers contributed very little to this process, but they also became involved because of the reminder system,” he added.

Another important role of U-WIN is tackling the so-called zero-dose children—those who have never been vaccinated.

“About 4–5 per cent of our eligible population falls into this category, meaning they have not received even the first pentavalent dose. On the face of it, 4–5 per cent may not seem like a huge problem. But when we look at the absolute numbers—out of 26 million—it translates into a very large number, which we cannot afford to miss. So tracking helps identify these children through the micro-plan system”.

U-WIN Enables Life-course Immunization

Also read: World Immunization Week: Vaccines Are Like Insurance, They’re Safe—Take Them, Says Dr NK Arora

“When a child is vaccinated, we know when boosters are due—at one and a half years, then at five years. But none of us remembers this. Even among well-informed parents, this is often forgotten. This system helps address that gap,” Dr. Arora said.

Further, when the same individual becomes eligible for vaccines like HPV—typically between 9 and 14 years—there is again a gap that needs to be addressed.

Certification is another benefit, as it creates a documented process, particularly for programs like oral polio vaccination.

Dr. Arora highlighted that in case of any future pandemic-like situation that requires repeated vaccinations, “we have a mechanism in place”.

“This IT platform has truly transformed the system. There is also a lot of discussion about using similar platforms for TB patients, pregnant women, and other flagship programs like non-communicable diseases. So, for India, digitalisation is at its best when we talk about U-WIN.”